5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grant A. McArthur(The University of Melbourne), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Edward McKenna(Roche (United Kingdom)), Haocheng Li(Roche (Canada)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), S.C. Bowen Jones(Colorado Permanente Medical Group), Athina Voulgari(Roche (United Kingdom)), Daniil Stroyakovskiy(Shikoku Cancer Center), James Larkin(Trinity College Dublin), L. Thomas(University of Liverpool), Antoni Ribas(University of California, Los Angeles), Jessie J. Hsu, Claus Garbe(University of Tübingen), Victoria Atkinson(Greenslopes Private Hospital), Brigitte Dréno(Nantes Université)

Clinical Cancer Research

June 22, 2021

Cited by 182

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2014|5.3k

|Journal of Clinical Investigation|2017|3.9k

|New England Journal of Medicine|2019|3.7k

5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study